The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate-Severe Crohn's Disease: A Systematic Review.

Pharmaceuticals (Basel) · 2023 · PMC10674451 · PMID 38004446

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

[ 47 ], vedolizumab treatment in the maintenance phase improved both clinical remission and clinical response, although the latter did not reach statistical significance compared to the placebo group.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.